Candesartan Effect in Second Stage Arterial Hypertension
Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Stage II Hypertension
Intervention: Candesartan Cilexetil (Drug); Hydrochlorothiazide (Drug); Candesartan Cilexetil (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: AstraZeneca Official(s) and/or principal investigator(s):
Dong Hoon Choi, Principal Investigator, Affiliation: Severance Hospital
Joonwoo Bahn, Study Director, Affiliation: AstraZeneca Korea
Overall contact:
AstraZeneca Korea Clinical, Study Information, Phone: 82 2 2188 0951, Email: minjee.nam@astrazeneca.com
Summary
To compare the changes in mean sitting DBP from baseline after 4 weeks of therapy with either
candesartan cilexetil/HCT combination therapy or candesartan cilexetil monotherapy regimen
Clinical Details
Official title: Open-Label, Randomised, 2-Arm Parallel Group, Multicentre, 8-Week, Phase IV Study to Assess the Antihypertensive Efficacy and Safety of the Candesartan Cilexetil 16 mg and Hydrochlorothiazide 12.5 mg Combination Therapy in Comparison With Candesartan 16 mg Monotherapy in Hypertensive Adults
Study design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: changes in mean sitting DBP
Secondary outcome: mean sitting SBP from baseline
Eligibility
Minimum age: 18 Years.
Maximum age: 70 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Stage II essential hypertension (SBP≥ 160 or DBP≥100 mmHg), untreated, or treated with
a maximum of 2 class of antihypertensive drugs
Exclusion Criteria:
- Current serum-creatinine >3 mg/dL, Current serum-potassium >5. 5 mmol/L, 16.
- Pregnant or lactating women or women of childbearing potential who were not protected
from pregnancy
Locations and Contacts
AstraZeneca Korea Clinical, Study Information, Phone: 82 2 2188 0951, Email: minjee.nam@astrazeneca.com
Research Site, Seoul, Korea, Republic of; Recruiting
Additional Information
Starting date: February 2008
Last updated: September 22, 2008
|
